The new findings aren’t enough to change those guidelines, said lead researcher Dr. Jeffrey Kaiser, of Baylor College of Medication in Houston. We have to be very careful about interpreting this, because it’s retrospective data from an individual infirmary, he said. This is just one piece of the puzzle. But given the chance this research raises – – that actually transient hypoglycemia could harm infants’ brains – – even more research is necessary, Kaiser said.Although several large proof-of-principle studies have confirmed the high sensitivity and specificity of cfDNA testing for the detection of trisomy 21, most of these scholarly studies have included just selected populations of high-risk women who were sampled before invasive testing. You can find more limited data available on the functionality of cfDNA screening in the overall pregnancy population.2-4 In this blinded, prospective study, called the Noninvasive Examination of Trisomy study, we tested the hypothesis that cfDNA testing has better performance than standard first-trimester screening in risk assessment for trisomy 21 in a big, unselected population of women presenting for aneuploidy screening.